|Bid||84.40 x 900|
|Ask||95.00 x 1100|
|Day's Range||83.02 - 87.25|
|52 Week Range||62.88 - 97.10|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.64|
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published this article and predicted that US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term bonds. Investors who agreed with […]
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the San Francisco Business Times "40 Under 40" list highlights the Bay Area's best and brightest young business and community leaders. Dr. Balakrishnan is the only woman biotech leader to be included in this year's list.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of BioMarin...
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biomarin (BMRN) just recently announced that the FDA has accepted for Priority Review the BLA for ValRox (valoctocogene roxaparvovec) for adults with hemophilia A, notes biotech expert John McCamant, editor of The Medical Technology Stock Letter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A. This acceptance by the FDA marks the first marketing application accepted for a gene therapy product for any type of hemophilia in the United States.
Investors have become more comfortable with the likes of UnitedHealth as Elizabeth Warren’s political fortunes have soured.
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February 26, 2020 at 10:00am ET in New York City and the Cowen and Company 40th Annual Health Care Conference on March 3, 2020 at 10:40am ET in Boston. To access the events that are accessible by live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.
As more drug companies subsidize the cost of the genetic test, more patients can be tested and, potentially, matched to the companies' drugs.
The gene therapy company is expected to introduce hemophilia drug that is projected to generate revenue of $1.2 billion by 2024 Continue reading...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman. Mr. Spiegelman will remain as an employee and senior advisor until September 1, 2020 to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Brian R. Mueller, Senior Vice President, Finance and Chief Accounting Officer, has assumed the role of acting Chief Financial Officer. The Company is initiating an internal and external search for the role of Chief Financial Officer.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 26, at 4:30 p.m. ET to discuss fourth quarter and full year 2019 financial results and provide a general business update.